The problem
CMV is a common virus which can usually be controlled by the immune system. Over half of the world’s population are currently infected with CMV for life.
Transplant patients are more vulnerable to CMV infection because the medications used to protect their new kidney also impact how well their immune system can fight infection. For these individuals, CMV infection can cause serious problems potentially leading to severe illness and an increased chance of kidney rejection.
CMV can also be passed on during pregnancy, so is potentially problematic for unborn babies, since they do not have a working immune system yet, so rely on their mother for protection. Therefore, an effective and safe vaccine is needed to protect these vulnerable groups.
Previous trials of CMV vaccines involving kidney transplant patients, have shown that around half of patients can be protected through vaccination using one single protein that fights infection, called an antibody.
- The Renal Warrior Project. Join Now
- Source: https://www.kidneyresearchuk.org/2024/06/12/protecting-vulnerable-individuals-from-cytomegalovirus-a-new-approach/